Abstract |
Pentostatin is an adenosine deaminase (ADA) inhibitor with antineoplastic activity. CD26 is a surface glycoprotein with a key role in T cell function as the ADA binding protein. We conducted a phase II study to evaluate pentostatin efficacy in relapsed T- non-Hodgkin's lymphoma (T-NHL) and to correlate response with tumor CD26 expression. We also examined the lymphopenic effect of pentostatin on CD26+ T lymphocytes. Eighteen patients were registered for the study. Pentostatin was administered as intravenous bolus daily over 3 days at an initial dose of 5 mg/m(2)/day, repeated every 4 weeks. CD26 surface expression on tumor cells and T lymphocytes was determined by flow cytometry. Out of 14 patients evaluable for response, there was 1 (7%) complete response (CR) and 6 (43%) partial responses (PR). Median progression-free survival for responders was 6 months (range: 2-15 months); median number of courses was 4 (range: 1-6). Responders included 1 of 2 CD26+ and 5 of 9 CD26- cases. Pentostatin also specifically depleted CD26+ rather than CD26- T lymphocytes, potentially associated with immunosuppression. We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications.
|
Authors | Nam H Dang, Fredrick B Hagemeister, Madeleine Duvic, Jorge E Romaguera, Anas Younes, Dan Jones, Barry Samuels, Luis E Fayad, Barbara Pro, Felipe Samaniego, Andreas Sarris, Andre Goy, Peter McLaughlin, Ann T Tong, Pamela L Walker, Lili Paz Tiongson, Terry L Smith, Yang O Huh, Chikao Morimoto, Maria A Rodriguez |
Journal | Oncology reports
(Oncol Rep)
2003 Sep-Oct
Vol. 10
Issue 5
Pg. 1513-8
ISSN: 1021-335X [Print] Greece |
PMID | 12883733
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibiotics, Antineoplastic
- Pentostatin
- Dipeptidyl Peptidase 4
|
Topics |
- Adult
- Aged
- Antibiotics, Antineoplastic
(adverse effects, therapeutic use)
- Dipeptidyl Peptidase 4
(biosynthesis)
- Dose-Response Relationship, Drug
- Female
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy)
- Lymphoma, T-Cell
(drug therapy)
- Male
- Middle Aged
- Pentostatin
(adverse effects, therapeutic use)
- T-Lymphocytes
(metabolism)
- Time Factors
- Treatment Outcome
|